TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06773117: Efficacy/Safety of Susu Xiao'er Zhike Granules for Children's Cold-Induced Cough (Wind-Cold Syndrome): Multicenter, Randomized, Double-Blind, Low-Dose Controlled Phase III Trial

Sponsor: Tasly Pharmaceutical Group Co., Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,173,128

Rescue Site Savings

+$7,354,464

Unlock Full NCT06773117 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06773117 Rescue Dossier →